Insight

Sep 21, 2024, 15:21

Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients

Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X:

“Out now in Nature Medicine ESMO24! In BELLINI, patients with early-stage TNBC received neoadjuvant Nivolumab with or without Ipilimumab, leading to ctDNA clearance & promising clinical response rates, especially in preselected patients with high TIL levels.”

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Authors: Iris Nederlof, Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen, Noor A. M. Bakker, Adrianne L. Rolfes, Hannah Garner, Bram Boeckx, Joleen J. H. Traets, Ingrid A. M. Mandjes, Michiel de Maaker, Thomas van Brussel, Maksim Chelushkin, Elisa Champanhet, Marta Lopez-Yurda, Koen van de Vijver, José G. van den Berg, Ingrid Hofland, Natasja Klioueva, Ritse M. Mann, Claudette E. Loo, Frederieke H. van Duijnhoven, Victoria Skinner, Sylvia Luykx, Emile Kerver, Ekaterina Kalashnikova, Marloes G. J. van Dongen, Gabe S. Sonke, Sabine C. Linn, Christian U. Blank, Karin E. de Visser, Roberto Salgado, Lodewyk F. A. Wessels, Caroline A. Drukker, Ton N. Schumacher, Hugo M. Horlings, Diether Lambrechts & Marleen Kok.

Source: Ulrike Harjes/X

Adrianne L. Rolfes BELLINI Bram Boeckx cancer Caroline A. Drukker Christian U. Blank Claudette E. Loo clinical response ctDNA Diether Lambrechts & Marleen Kok Ekaterina Kalashnikova Elisa Champanhet Emile Kerver ESMO24 Frederieke H. van Duijnhoven Gabe S. Sonke Hannah Garner Hugo M. Horlings Ingrid A. M. Mandjes Ingrid Hofland ipilimumab Iris Nederlof Joleen J. H. Traets José G. van den Berg Karin E. de Visser Koen van de Vijver Lodewyk F.A. Wessels Maksim Chelushkin Manon de Graaf Marloes G. J. van Dongen Marta Lopez-Yurda Michiel de Maaker Natasja Klioueva Nature Medicine nivolumab Noor A. M. Bakker Olga I. Isaeva OncoDaily Oncology Ritse M. Mann Robbert C. A. M. Gielen Roberto Salgado Sabine C. Linn Sylvia Luykx Thomas van Brussel TIL TNBC Ton N. Schumacher Ulrike Harjes Victoria Skinner

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage